Endocare cryotherapy study shows 100% survival in prostate-cancer treatment

By Elaine Rigoli

Tampa, Fla., May 24 - Endocare, Inc. said an eight-year study that involved using cryotherapy as a primary, or first-line, treatment on 182 men with prostate cancer showed a 100% survival rate.

Further, Endocare said that after eight years, 86% of follow-up biopsies showed no evidence of disease and Astro biochemical recurrence-free survival rate was 81%.

This study also showed very few side effects, including only 2.2% incontinence, 2.3% rectal pain and no reported incidents of fistula following the procedure, according to a company news release.

This data was announced Wednesday at the annual meeting of the American Urological Association in Atlanta.

Endocare, based in Irvine, Calif., develops minimally invasive technologies for tissue and tumor ablation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.